Product Images Aripiprazole
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Aripiprazole NDC 68071-3848 by Nucare Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 68071 3848 3
This is a product description for Aripiprazole 5mg tablets. It contains important information such as the manufacturer's label, NDC codes, lot numbers, expiration dates, and the GTIN. The warning on the label cautions users to keep the medication out of reach of children. It also provides instructions to call a doctor for medical advice regarding side effects and how to report side effects to the FDA. Additionally, it specifies the controlled temperature for storing the medication at 68-77°F.*
camber-logo - camber logo
figure1 - figure1
This text provides information on the effect of various drugs on the pharmacokinetics of aripiprazole. It includes data on the PK changes and 90% confidence intervals for aripiprazole when co-administered with different types of drugs such as CYP3A4 inhibitors like ketoconazole, CYP2D6 inhibitors, antiepileptic drugs like carbamazepine, and gastric acid blockers like famotidine. Additionally, it mentions potential drug interactions with lorazepam. The text seems to present a comparative analysis of the changes in aripiprazole exposure relative to a reference scenario without interacting drugs.*
figure2 - figure2
figure3 - figure3
figure4 - figure4
This text provides information on special populations in a study, including individuals with cvpads, poor metabolizer ALC, different genders, ages, and varying degrees of hepatic and renal impairment. The text also mentions a change chart related to aripiprazole.*
figure5 - figure5
figure6 - figure6
figure7 - figure7
figure8 - figure8
figure9 - figure9
This text provides information on the least squares mean change in YGTSS (Yale Global Tic Severity Scale) total TIC (Tourette's syndrome) score attributed to different treatments, including Abilify Low, Abilify High, and Placebo. The data indicates the change in the YGTSS total TIC score from baseline for these treatment groups.*
structure-1 - structure 1
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
